Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-02-11

Clinical Trial Update: Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) [Phase 3]

View source ↗

Summary

Phase 3 SUNRISE 1 study evaluating the efficacy and safety of lemborexant in adults aged 55 and older with insomnia disorder has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lemborexant (lemborexant)

Snippet

Sponsor: Eisai Inc. | Conditions: Insomnia | Phase 3 | Status: COMPLETED | Results posted: 2020-02-11